https://scholars.lib.ntu.edu.tw/handle/123456789/551116
標題: | HBV-DNA level at 6 months of entecavir treatment predicts HBeAg loss in HBeAg-positive chronic hepatitis B patients | 作者: | Peng C.-Y. Hsieh T.-C. Hsieh T.-Y. Tseng K.-C. Lin C.-L. TUNG-HUNG SU TAI-CHUNG TSENG Lin H.H. Wang C.-C. JIA-HORNG KAO |
公開日期: | 2015 | 出版社: | Elsevier B.V. | 卷: | 114 | 期: | 4 | 起(迄)頁: | 308-313 | 來源出版物: | Journal of the Formosan Medical Association | 摘要: | Background/Purpose: To evaluate whether on-treatment HBV-DNA level could predict the treatment response to entecavir in hepatitis B e antigen (HBe)-positive chronic hepatitis B (CHB) patients. Methods: A total of 68 treatment-na?ve HBeAg-positive patients (75% male, mean age at 46.6±11.9 years) receiving at least 2 years of entecavir therapy were enrolled. The primary therapeutic endpoint was HBeAg loss. On-treatment complete virological response was defined as serum HBV-DNA<63IU/mL. Results: The median baseline alanine aminotransferase (ALT) and HBV-DNA levels were 199.5 (27-1622) U/L and 7.7 (3.8-13.2) log10IU/mL, respectively. The median treatment duration was 31.7 (24.3-69.6) months. The rate of HBeAg loss at 2 years was 30.9%. By univariate analysis, on-treatment complete virological response at Month 6 was associated with HBeAg loss at 2 years (p=0.019). After adjustment for age, sex, cirrhosis, baseline ALT, and HBV-DNA levels, this factor remained significant in multivariate analysis (odds ratio: 4.35; 95% confidence interval: 1.24-15.24, p=0.021). Conclusion: On-treatment complete virological response at Month 6 is a favorable factor predictive of HBeAg loss at 2 years of entecavir therapy. Therefore, measurement of serum HBV-DNA level at 6 months of entecavir therapy is optimal to predict HBeAg loss at 2 years of therapy in HBeAg-positive CHB patients. ? 2013. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-84925956969&doi=10.1016%2fj.jfma.2013.10.023&partnerID=40&md5=7a053e39a36f53758ad3facca0b5a416 https://scholars.lib.ntu.edu.tw/handle/123456789/551116 |
ISSN: | 0929-6646 | DOI: | 10.1016/j.jfma.2013.10.023 | SDG/關鍵字: | alanine aminotransferase; entecavir; hepatitis B core antigen; hepatitis B surface antigen; hepatitis B(e) antigen; antivirus agent; entecavir; guanine; hepatitis B(e) antigen; virus DNA; adolescent; adult; aged; alanine aminotransferase blood level; Article; controlled study; disease association; DNA virus; drug treatment failure; female; hepatitis B; Hepatitis B virus; human; human tissue; liver biopsy; liver cirrhosis; liver function test; major clinical study; male; multicenter study (topic); protein blood level; protein depletion; retrospective study; sample size; treatment duration; treatment response; analogs and derivatives; blood; follow up; Hepatitis B virus; Hepatitis B, Chronic; middle aged; multivariate analysis; odds ratio; prognosis; statistical model; Taiwan; treatment outcome; young adult; Adolescent; Adult; Aged; Alanine Transaminase; Antiviral Agents; DNA, Viral; Female; Follow-Up Studies; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Logistic Models; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Prognosis; Retrospective Studies; Taiwan; Treatment Outcome; Young Adult |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。